Literature DB >> 9227167

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis.

R Munro1, E Morrison, A G McDonald, J A Hunter, R Madhok, H A Capell.   

Abstract

OBJECTIVE: To determine the effect of intramuscular gold and oral hydroxychloroquine (HCQ) on the lipid profile of patients with rheumatoid arthritis (RA).
METHOD: A prospective randomised clinical trial of 12 months' duration was performed in 100 RA patients. Data on clinical and laboratory parameters of disease activity, and fasting serum lipid samples was collected at baseline and at three monthly intervals over one year.
RESULTS: The expected second line response was seen with no significant difference in efficacy between the groups at 12 months. The HCQ group had a significant overall improvement in their lipid profile while there was a trend for lipid profiles in the gold group to worsen.
CONCLUSIONS: HCQ is an effective second line agent that has beneficial effects on serum lipids. This should be taken into account when choosing a disease modifying anti-rheumatic drug in patients who suffer from RA and who have significant cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227167      PMCID: PMC1752398          DOI: 10.1136/ard.56.6.374

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy.

Authors:  Sana Parveen; Rachel Jacob; Liza Rajasekhar; C Srinivasa; Iyyapu Krishna Mohan
Journal:  Indian J Clin Biochem       Date:  2016-04-22

Review 2.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.

Authors:  Jamie Robertson; Mike J Peters; Iain B McInnes; Naveed Sattar
Journal:  Nat Rev Rheumatol       Date:  2013-06-18       Impact factor: 20.543

3.  Dyslipidemia and rheumatoid arthritis.

Authors:  R D Situnayake; G Kitas
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

Review 4.  Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.

Authors:  Matxalen Amezaga Urruela; Maria E Suarez-Almazor
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

5.  Positive effect of hydroxychloroquine on lipid profiles of patients with rheumatoid arthritis: A Veterans Affair cohort.

Authors:  Myriam Guevara; Bernard Ng
Journal:  Eur J Rheumatol       Date:  2020-11-05

Review 6.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

Review 7.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.

Authors:  Mirella P Hage; Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-08       Impact factor: 3.565

8.  Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients.

Authors:  Jose Felix Restrepo; Inmaculada Del Rincon; Emily Molina; Daniel F Battafarano; Agustin Escalante
Journal:  J Clin Rheumatol       Date:  2017-04       Impact factor: 3.517

9.  Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats.

Authors:  Anil Pareek; P G Yeole; C R Tenpe; Nitin Chandurkar; Ravikiran Payghan
Journal:  Indian J Pharmacol       Date:  2009-06       Impact factor: 1.200

10.  Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Christina Charles-Schoeman; Xiaoyan Wang; Yuen Yin Lee; Ani Shahbazian; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; James O'Dell; Joan M Bathon; Harold Paulus; S Louis Bridges; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.